HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment

This study evaluated the interferon-free, oral combination of deleobuvir (non-nucleoside HCV NS5-RNA-polymerase inhibitor) and faldaprevir (HCV NS3/4A-protease inhibitor) with ribavirin in patients with HCV genotype-1b and moderate (Child-Pugh B [CPB], n = 17) or mild hepatic impairment (Child-Pugh...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:PLoS One
Auteurs principaux: Sarrazin, Christoph, Manns, Michael, Calleja, Jose Luis, Garcia-Samaniego, Javier, Forns, Xavier, Kaste, Renee, Bai, Xiaofei, Wu, Jing, Stern, Jerry O.
Format: Artigo
Langue:Inglês
Publié: Public Library of Science 2016
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5193411/
https://ncbi.nlm.nih.gov/pubmed/28030579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0168544
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires